The SOUL trial showed that oral semaglutide was safe in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.

The SOUL trial compared oral semaglutide vs. placebo on top of standard care in patients with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both. Read Healio’s ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

Semaglutide increased maximum walking distance ... end-stage kidney disease and cardiovascular death in adults with T2D and chronic kidney disease.

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

Medscape Medical News, March 31, 2025 ACC 2025 Oral GLP-1 Receptor Agonist Reduces CV Risk Oral semaglutide ... enhance the early detection of chronic kidney disease in low-risk patients, a ...

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Beyond its weight loss and diabetes control, semaglutide is increasingly being studied for its potential role in treating a range of chronic illnesses, from heart disease to kidney failure.